BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22153340)

  • 21. M3 muscarinic acetylcholine receptor antagonists: SAR and optimization of bi-aryl amines.
    Budzik B; Wang Y; Shi D; Wang F; Xie H; Wan Z; Zhu C; Foley JJ; Nuthulaganti P; Kallal LA; Sarau HM; Morrow DM; Moore ML; Rivero RA; Palovich M; Salmon M; Belmonte KE; Laine DI; Jin J
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1686-90. PubMed ID: 19243945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concentration of matrix metalloproteinase-9 in serum of patients with chronic obstructive pulmonary disease and a degree of airway obstruction and disease progression.
    Brajer B; Batura-Gabryel H; Nowicka A; Kuznar-Kaminska B; Szczepanik A
    J Physiol Pharmacol; 2008 Dec; 59 Suppl 6():145-52. PubMed ID: 19218638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery, SAR and X-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk).
    Moriarty KJ; Takahashi H; Pullen SS; Khine HH; Sallati RH; Raymond EL; Woska JR; Jeanfavre DD; Roth GP; Winters MP; Qiao L; Ryan D; DesJarlais R; Robinson D; Wilson M; Bobko M; Cook BN; Lo HY; Nemoto PA; Kashem MA; Wolak JP; White A; Magolda RL; Tomczuk B
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5545-9. PubMed ID: 18819799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic obstructive pulmonary disease in a new concept.
    Murărescu ED; Mitrofan EC; Mihailovici MS
    Rom J Morphol Embryol; 2007; 48(3):207-14. PubMed ID: 17914487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13.
    Tommasi RA; Weiler S; McQuire LW; Rogel O; Chambers M; Clark K; Doughty J; Fang J; Ganu V; Grob J; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Melton R; Springer C; Walker M; Zhang J; Zhu L; Shultz M
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6440-5. PubMed ID: 21937229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Series "matrix metalloproteinases in lung health and disease": Matrix metalloproteinases in COPD.
    Churg A; Zhou S; Wright JL
    Eur Respir J; 2012 Jan; 39(1):197-209. PubMed ID: 21920892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data.
    Mantell SJ; Stephenson PT; Monaghan SM; Maw GN; Trevethick MA; Yeadon M; Walker DK; Selby MD; Batchelor DV; Rozze S; Chavaroche H; Lemaitre A; Wright KN; Whitlock L; Stuart EF; Wright PA; Macintyre F
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4471-5. PubMed ID: 19501510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A therapeutic role for matrix metalloproteinase inhibitors in lung diseases?
    Vandenbroucke RE; Dejonckheere E; Libert C
    Eur Respir J; 2011 Nov; 38(5):1200-14. PubMed ID: 21659416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rho kinase as a therapeutic target in the treatment of asthma and chronic obstructive pulmonary disease.
    Fernandes LB; Henry PJ; Goldie RG
    Ther Adv Respir Dis; 2007 Oct; 1(1):25-33. PubMed ID: 19124345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis of radioiodinated probes targeted toward matrix metalloproteinase-12.
    Hagimori M; Temma T; Kudo S; Sano K; Kondo N; Mukai T
    Bioorg Med Chem Lett; 2018 Jan; 28(2):193-195. PubMed ID: 29191557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease.
    Bolton CE; Stone MD; Edwards PH; Duckers JM; Evans WD; Shale DJ
    Chron Respir Dis; 2009; 6(2):81-7. PubMed ID: 19411568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zl-n-91, a selective phosphodiesterase 4 inhibitor, suppresses inflammatory response in a COPD-like rat model.
    Wang YJ; Jiang YL; Tang HF; Zhao CZ; Chen JQ
    Int Immunopharmacol; 2010 Feb; 10(2):252-8. PubMed ID: 19914404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.
    Baragi VM; Becher G; Bendele AM; Biesinger R; Bluhm H; Boer J; Deng H; Dodd R; Essers M; Feuerstein T; Gallagher BM; Gege C; Hochgürtel M; Hofmann M; Jaworski A; Jin L; Kiely A; Korniski B; Kroth H; Nix D; Nolte B; Piecha D; Powers TS; Richter F; Schneider M; Steeneck C; Sucholeiki I; Taveras A; Timmermann A; Van Veldhuizen J; Weik J; Wu X; Xia B
    Arthritis Rheum; 2009 Jul; 60(7):2008-18. PubMed ID: 19565489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 4-Phenyl-7-azaindoles as potent and selective IKK2 inhibitors.
    Liddle J; Bamborough P; Barker MD; Campos S; Cousins RP; Cutler GJ; Hobbs H; Holmes DS; Ioannou C; Mellor GW; Morse MA; Payne JJ; Pritchard JM; Smith KJ; Tape DT; Whitworth C; Williamson RA
    Bioorg Med Chem Lett; 2009 May; 19(9):2504-8. PubMed ID: 19349179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD.
    Shan WJ; Huang L; Zhou Q; Jiang HL; Luo ZH; Lai KF; Li XS
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1523-6. PubMed ID: 22297114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sulphonamides: Deserving class as MMP inhibitors?
    Jain P; Saravanan C; Singh SK
    Eur J Med Chem; 2013 Feb; 60():89-100. PubMed ID: 23287054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.
    De Savi C; Morley AD; Nash I; Karoutchi G; Page K; Ting A; Gerhardt S
    Bioorg Med Chem Lett; 2012 Jan; 22(1):271-7. PubMed ID: 22153941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MMP-9 protein level does not reflect overall MMP activity in the airways of patients with COPD.
    Lowrey GE; Henderson N; Blakey JD; Corne JM; Johnson SR
    Respir Med; 2008 Jun; 102(6):845-51. PubMed ID: 18328682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases.
    Hu J; Van den Steen PE; Sang QX; Opdenakker G
    Nat Rev Drug Discov; 2007 Jun; 6(6):480-98. PubMed ID: 17541420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Matrix metalloproteinases in the pathogenesis of asthma and COPD: implications for therapy.
    Suzuki R; Miyazaki Y; Takagi K; Torii K; Taniguchi H
    Treat Respir Med; 2004; 3(1):17-27. PubMed ID: 15174890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.